Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial. Issue 8 (29th March 2013)

• Record Type: Journal Article
• Authors: Lee, S.‐H.; Park, H.‐K.; Ryu, W.‐S.; Lee, J.‐S.; Bae, H.‐J.; Han, M.‐K.; Lee, Y.‐S.; Kwon, H.‐M.; Kim, C. K.; Park, E.‐S.; Chung, J.‐W.; Jung, K.‐H.; Roh, J.‐K.
• Is Part Of: European journal of neurology. Volume 20:Issue 8(2013:Aug.)
• Page Start: 1161
• Page End: 1169
• Publication Date: 2013-03-29
• Subjects: Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12140
• Languages: English
• ISSNs: 1351-5101

Abstract

<abstract abstract-type="main" id="ene12140-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ene12140-sec-0001" sec-type="section"> <title>Background and purpose</title> <p>We investigated the effect of celecoxib, a selective inhibitor of cyclo‐oxygenase 2, in patients with intracerebral hemorrhage (ICH).</p> </sec> <sec id="ene12140-sec-0002" sec-type="section"> <title>Methods</title> <p>We conducted a multicenter, randomized, controlled, and open with blinded end‐point trial of 44 Korean patients 18 years or older with ICH within 24 h of onset. The intervention group (<italic>n </italic>= 20) received celecoxib (400 mg twice a day) for 14 days. The control group (<italic>n </italic>= 24) received the standard medical treatment for ICH. The primary end‐point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th ± 1 day (cut‐off value, 20%).</p> </sec> <sec id="ene12140-sec-0003" sec-type="section"> <title>Results</title> <p>The time from onset to computed tomography scan slightly differed between groups (177 ± 160 min for control vs. 297 ± 305 min for the celecoxib group; <italic>P </italic>= 0.10). In the primary end‐point analysis using cut‐off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (<italic>P </italic>= 0.005). With respect to the secondary end‐points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (<italic>P </italic>= 0.046). In addition, the expansion rate of PHE at follow‐up tended to be higher in the control group than in the celecoxib group (90.6 ± 91.7% vs. 44.4 ± 64.9%; <italic>P </italic>= 0.058).</p> </sec> <sec id="ene12140-sec-0004" sec-type="section"> <title>Conclusions</title> <p>In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.</p> </sec> </abstract>